Viewing Study NCT02953457

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:36 PM
Ignite Modification Date: 2026-01-03 @ 8:39 PM
Study NCT ID: NCT02953457
Status: COMPLETED
Last Update Posted: 2024-11-19
First Post: 2016-11-01
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Sponsor: Roswell Park Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None BRCA1 Gene Mutation View
None BRCA2 Gene Mutation View
None Ovarian Serous Adenocarcinoma View
None Recurrent Fallopian Tube Carcinoma View
None Recurrent Ovarian Carcinoma View
None Recurrent Primary Peritoneal Carcinoma View
Keywords: